Drug intelligence / Profile preview

amcenestrant microtracer

Development stage: Discontinued
Lead developer: Sanofi
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Oral, Intravenous

Overview

A carbon-14 radiolabeled version of amcenestrant (SAR439859) used as a microtracer in clinical studies to assess drug absorption, metabolism, and excretion. The parent compound, amcenestrant, is an orally active, nonsteroidal selective estrogen receptor degrader (SERD) with potent ER antagonist properties (EC50 of 0.2 nM for ERα degradation). The microtracer allows researchers to track the drug's pharmacokinetics and metabolic profile with high sensitivity.

Other names: [14C]-amcenestrant microtracer

Targets

ESR1 (ERα)

Beyond the preview

Go deeper on amcenestrant microtracer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amcenestrant microtracer.

Explore the full profile